Breaking News

Tweet TWEET

Gemoscan Canada Announces Secured Loan, Debenture and Issuance of Bonus Shares

Gemoscan Canada Announces Secured Loan, Debenture and Issuance of Bonus Shares

TORONTO, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. ("Gemoscan" or
the "Corporation") – (TSX-V:GES) wishes to announce that it has entered into a
secured loan agreement with an arm's length party (the "Lender"). The Lender
has provided the Corporation a $175,000 loan (the "Loan"), bearing interest at
a rate of 9% per annum and which matures on November 28, 2013. Additionally,
in connection with the Loan, the Lender will receive a bonus of 358,974 Class
A Shares (the "Shares") in the capital of the Corporation at a price of
$0.0975 per Share. All Shares are subject to a statutory four month plus one
day hold period from November 28, 2012.

ABOUT GEMOSCAN CANADA, INC.

Gemoscan is an industry leader in food intolerance management and maintains a
first-to-market position with Canada wide distribution through select retail
partners. Founded in 2003, using its proprietary patented technology; Gemoscan
develops, owns and markets comprehensive food sensitivity and dietary
management solutions for consumers, including the HEMOCODE^TM Food Intolerance
System, a personalized naturopathic nutritional program that promotes
well-being. Gemoscan is the first and only provider to commercialize a food
intolerance management solution directly to consumers in partnership with
retailers, and today offers the most comprehensive services available.

Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange
(TSX-V) under the symbol GES and is quoted on the Munich, Frankfurt and
Stuttgart Stock Exchanges under the symbol 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information". All
statements, other than statements of historical fact that address activities,
events or developments that Gemoscan believes, expects or anticipates will or
may occur in the future. These forward-looking statements reflect the current
expectations or beliefs of Gemoscan based on information currently available
to Gemoscan. Forward-looking statements are subject to a number of significant
risks and uncertainties and other factors that may cause the actual results of
Gemoscan to differ materially from those discussed in the forward-looking
statements, and even if such actual results are realized or substantially
realized, there can be no assurance that they will have the expected
consequences to, or effects on Gemoscan. Any forward-looking statement speaks
only as of the date on which it is made and, except as may be required by
applicable securities laws, Gemoscan disclaims any intent or obligation to
update any forward-looking statement, whether as a result of new information,
future events or results or otherwise. Although Gemoscan believes that the
assumptions inherent in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of future performance and
accordingly undue reliance should not be put on such statements due to the
inherent uncertainty therein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

CONTACT: Gemoscan Canada, Inc.
         Brian Kalish
         Director, President and CEO
         (416) 650-1200
         Email: bkalish@hemocode.com
        
         Company website: www.gemoscan.com
 
Press spacebar to pause and continue. Press esc to stop.